Skip to main content
. 2016 Jun 2;4(7):e464–e473. doi: 10.1016/S2214-109X(16)30096-1

Table 1.

Baseline characteristics of the intention-to-treat population

Placebo N=891 Co-trimoxazole N=887
Age (months) 10·8 (6·9–16·7) 11·2 (7·2–16·7)
Younger than 6 months 158 (18%) 148 (17%)
Sex
Female 428 (48%) 447 (50%)
Male 463 (52%) 440 (50%)
Mother is primary caretaker 838 (94%) 823 (93%)
Caretaker completed primary education (n/total N)* 359/573 (63%) 347/577 (60%)
Currently breastfeeding 551 (62%) 541 (61%)
Received pneumococal conjugate vaccine 524 (59%) 504 (57%)
Urban site 680 (76%) 676 (76%)
Nutritional oedema 149 (17%) 151 (17%)
MUAC (cm) 10·6 (1·09) 10·6 (1·05)
MUAC-for-age Z score −3·83 (1·05) −3·81 (0·99)
Weight-for-length Z score§ −3·35 (1·26) −3·32 (1·27)
Weight-for-age Z score§ −4·01 (1·12) −3·96 (1·09)
Length-for-age Z score −2·91 (1·67) −2·82 (1·64)
Head circumference-for-age Z score* −1·82 (1·47) −1·73 (1·40)
Haemoglobin (g/L) 98·0 (21·4) 98·0 (22·4)
Clinical signs of rickets 129 (14%) 118 (13%)
Ocular signs of vitamin A deficiency 3 (<1%) 1 (<1%)
Cerebral palsy 34 (4%) 32 (4%)
Known tuberculosis at enrolment 31 (3%) 36 (4%)
Index admission for pneumonia 484 (54%) 474 (53%)
Index admission for diarrhoea 506 (57%) 515 (58%)
Treated for shock before enrolment 84 (9%) 100 (11%)
Impaired consciousness before enrolment 57 (6%) 56 (6%)
Days from admission to enrolment 6 (4–8) 6 (4–8)

Data are median (IQR), n (%), or mean (SD). MUAC=mid-upper-arm circumference.

*

Data obtained from April, 2011.

Received at least one dose of pneumococcal conjugate vaccine at enrolment.

Excludes infants younger than 3 months, because no WHO (2006) reference exists for younger than this age.

§

Excludes children with kwashiorkor (oedematous malnutrition).